The emergence of the Cicada variant, a highly mutated COVID-19 strain, has sparked concern and curiosity among health experts and the public alike. This new variant, officially named BA.3.2, has been likened to a cicada due to its long dormancy and sudden, noisy resurgence. As of March 2026, Cicada has been detected in 23 countries, with a notable presence in parts of Europe, where it accounts for up to 30% of cases.
What makes this variant particularly intriguing is its ability to evade some vaccines. Virologist Andrew Pekosz highlights that Cicada's many mutations may cause it to appear different to our immune systems, potentially reducing the effectiveness of existing vaccines. However, experts like Dr. Marc Siegel caution that it's too early to predict the variant's impact on a community-wide scale, as its prevalence remains relatively low.
The Cicada's Journey
The Cicada variant's journey began in South Africa in November 2024, but it didn't gain significant traction until September 2025. Its first appearance in the US was in June 2025, when a traveler from the Netherlands passed through San Francisco International Airport. By January 2026, Cicada had been identified in clinical samples from US patients, and as of February 11, it had been detected in various states, including New York, New Jersey, and Connecticut.
Dr. Robery H. Hopkins Jr. suggests that Cicada could potentially drive a summer COVID surge and become the dominant strain in the US. However, he emphasizes that this outcome is not certain.
Symptoms and Severity
One thing that immediately stands out is that the Cicada variant doesn't seem to cause significantly different symptoms from previous strains. Common symptoms include cough, fever, sore throat, congestion, shortness of breath, fatigue, headache, loss of smell or taste, and gastrointestinal issues. These symptoms can vary in severity and may resolve with rest, hydration, and over-the-counter medications. Interestingly, the variant can also cause asymptomatic infections, meaning some carriers won't feel sick but can still transmit the virus.
Public Health Implications
The Cicada variant's potential to evade vaccines raises a deeper question about our ongoing battle with COVID-19. While there's currently no evidence that Cicada causes more severe illness on a population level, the variant's ability to spread and its potential impact on vaccine effectiveness are cause for concern. COVID-19 continues to be a significant public health threat, contributing to hundreds of thousands of hospitalizations and deaths in the US alone in 2025.
Expert Insights
Experts emphasize that while BA.3.2 has many spike protein mutations that could reduce immunity, vaccines still provide protection, especially against severe disease. Dr. Adolfo GarcĂa-Sastre suggests that the current vaccine likely still has some effectiveness against Cicada, although the exact level of protection is not yet clear.
Conclusion
The emergence of the Cicada variant serves as a reminder that the COVID-19 pandemic is far from over. While we've made significant strides in managing the virus, the ongoing evolution of strains like Cicada highlights the need for continued vigilance, research, and adaptation in our public health strategies. As we navigate this new phase of the pandemic, staying informed, vaccinated, and aware of potential symptoms remains crucial.
